Neurodegenerative disease management最新文献

Longitudinal patterns of loss of independence in Parkinson disease. 帕金森病独立性丧失的纵向模式。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-06-04 DOI: 10.1080/17582024.2025.2514982

Tsung-Ying Lee, Lisa M Shulman, Ann L Gruber-Baldini, Julia F Slejko, Mathangi Gopalakrishnan, Eberechukwu Onukwugha

{"title":"Longitudinal patterns of loss of independence in Parkinson disease.","authors":"Tsung-Ying Lee, Lisa M Shulman, Ann L Gruber-Baldini, Julia F Slejko, Mathangi Gopalakrishnan, Eberechukwu Onukwugha","doi":"10.1080/17582024.2025.2514982","DOIUrl":"https://doi.org/10.1080/17582024.2025.2514982","url":null,"abstract":"Aim: To examine the longitudinal loss of independence (LOI) in Parkinson disease (PD) and introduce event visualization as a research tool.Methods: Early-stage PD patients seen by a movement disorders specialist from 2003-2020 were included. LOI, defined as needing help with activities of daily living (ADLs), was assessed using the modified Older Americans Resources and Services Daily Function Questionnaire. EventFlow software visualized LOI patterns.Results: The cohort included 296 patients (mean age 60.8; 61% male; 94% Hoehn & Yahr stages 1-2). At baseline, 91% were independent. LOI occurred in 133 patients for ≥ 1 ADL, and in 95 patients for ≥ 3 ADLs. Housework was the most frequent first ADL needing help (58 of 133), with a mean onset of 4.6 years. Among those with LOI, 57 (43%) regained independence at least once.Conclusion: LOI in PD shows both transient and persistent patterns. Event visualization may aid understanding of progression and support patient counseling.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary on taking medication as prescribed for multiple sclerosis: impact on relapses, disability, and healthcare costs. 简单的语言总结服用药物的规定多发性硬化症：对复发，残疾和医疗费用的影响。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-06-04 DOI: 10.1080/17582024.2025.2506949

Lilyana Amezcua, Terrie Livingston, Brooke Hayward, Jia Zhou, Mitzi J Williams

引用次数: 0

The silent saboteur: oxidative stress and the path to cognitive dysfunction. 沉默的破坏者：氧化应激和认知功能障碍的途径。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-05-27 DOI: 10.1080/17582024.2025.2510175

Tulia Fernanda Meira Garcia, Janaína Aparecida Favero Desio, Everton Ferreira de Souza, Silvana Fátima Costa Henkes, Luana Stangherlin Santos, Julcileia de Carvalho Muenho, Cinara Ludvig Gonçalves, Júlio César Claudino Dos Santos

{"title":"The silent saboteur: oxidative stress and the path to cognitive dysfunction.","authors":"Tulia Fernanda Meira Garcia, Janaína Aparecida Favero Desio, Everton Ferreira de Souza, Silvana Fátima Costa Henkes, Luana Stangherlin Santos, Julcileia de Carvalho Muenho, Cinara Ludvig Gonçalves, Júlio César Claudino Dos Santos","doi":"10.1080/17582024.2025.2510175","DOIUrl":"10.1080/17582024.2025.2510175","url":null,"abstract":"Oxidative stress (OS) plays a central role in age-related cognitive decline and neurodegeneration and is increasingly recognized as a key factor in the pathogenesis of Alzheimer's disease (AD) and Parkinson's disease (PD). Elevated OS biomarkers are detectable from the earliest stages of these disorders. In this critical narrative review, we explore the bioenergetic cascade underlying neurodegeneration, emphasizing pathophysiological alterations, mechanisms, and therapeutic targets. Recent evidence suggests that OS and impaired cellular energy dynamics are both early markers and downstream effects of neuroinflammation, contributing to symptom severity and reduced treatment efficacy. A deeper understanding of these interrelated processes is essential for the development of more effective interventions. Monitoring OS-related metabolites may offer a promising strategy for identifying therapeutic targets and enabling early clinical intervention, ultimately aiming to reduce neuroinflammation and improve patient outcomes in AD and PD.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-28"},"PeriodicalIF":2.3,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144160641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of antidepressants in early Huntington's Disease: a systematic review and meta-analysis. 抗抑郁药在早期亨廷顿病中的应用：一项系统回顾和荟萃分析

IF 2.3

Neurodegenerative disease management Pub Date : 2025-05-27 DOI: 10.1080/17582024.2025.2510145

Vishnu Tiwari, Sanjukta Dutta, Feras Alkharboush, Mario Renato Velit, Zelde Espinel

{"title":"Use of antidepressants in early Huntington's Disease: a systematic review and meta-analysis.","authors":"Vishnu Tiwari, Sanjukta Dutta, Feras Alkharboush, Mario Renato Velit, Zelde Espinel","doi":"10.1080/17582024.2025.2510145","DOIUrl":"https://doi.org/10.1080/17582024.2025.2510145","url":null,"abstract":"Background: While neuropsychiatric symptoms are common in Huntington's Disease (HD), there is a dearth of evidence about the effectiveness of psychotropic medication for treating behavioral and cognitive symptoms. This article systematically reviews and aggregates the evidence of the effects of antidepressants on individuals with early HD.Methods: A systematic review and random-effects meta-analysis of RCTs comparing antidepressants to placebo in individuals with HD was performed, with a focus on outcomes of executive functioning, functional capacity, mood, motor function, and adverse events.Results: A total of 4 studies with 123 of patients with early HD, of whom a total of 63 (51.2%) received an antidepressant, were identified in our search. In our pooled analysis, a modest but statistically significant improvement in mood resulted from antidepressant treatment in HD (OR -1.22; 95% CI -2.16,-0.27; p = 0.02). No significant differences in the other outcomes of interest were found following antidepressant exposure.Conclusions: Our investigation suggests that antidepressant use may modestly improve mood, but not ameliorate functional, cognitive, or movement-related symptoms in mild HD. Further studies involving novel agents, larger samples, and longer follow-up times are needed to better characterize the effect of antidepressants on neuropsychiatric symptoms in HD.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-8"},"PeriodicalIF":2.3,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gait analysis for Parkinson's disease using multiscale entropy. 基于多尺度熵的帕金森病步态分析。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-05-26 DOI: 10.1080/17582024.2025.2510842

Leianne Rose V Amisola, Ralph Joaquimn B Acosta, Hail Mariella D Arao-Arao, Vianca Nicole C Benitez, Ron Marrion T Chan, Anna Katrina G Co, Nicole Shandy F Cortez, Pj Brian F Galina, Michael Christian A Virata

{"title":"Gait analysis for Parkinson's disease using multiscale entropy.","authors":"Leianne Rose V Amisola, Ralph Joaquimn B Acosta, Hail Mariella D Arao-Arao, Vianca Nicole C Benitez, Ron Marrion T Chan, Anna Katrina G Co, Nicole Shandy F Cortez, Pj Brian F Galina, Michael Christian A Virata","doi":"10.1080/17582024.2025.2510842","DOIUrl":"https://doi.org/10.1080/17582024.2025.2510842","url":null,"abstract":"Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by motor dysfunction and complex gait abnormalities. Traditional linear methods often fail to capture the intricate movement patterns in PD. This review highlights Multiscale Entropy (MSE) as a promising tool for assessing gait dynamics, offering deeper insights into movement variability across multiple temporal scales. MSE distinguishes healthy and pathological gait patterns, enhancing early diagnosis and disease monitoring. Advances in wearable sensors, artificial intelligence, and machine learning have boosted MSE's clinical relevance by enabling real-time, personalized gait assessments. Despite these benefits, MSE faces challenges such as computational demands and the need for high-resolution data. Addressing these limitations through large-scale studies, standardized protocols, and integration of emerging technologies may support broader clinical adoption and the development of a robust normative database.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-14"},"PeriodicalIF":2.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring mechanisms of behavior change for healthcare professionals in cough and secretion management in ALS. 探讨医护人员在ALS患者咳嗽和分泌物管理中的行为改变机制。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-05-20 DOI: 10.1080/17582024.2025.2506954

Charlotte Massey, Esther Hobson, Alys Wyn Griffiths, Lucy Musson, Christopher McDermott

{"title":"Exploring mechanisms of behavior change for healthcare professionals in cough and secretion management in ALS.","authors":"Charlotte Massey, Esther Hobson, Alys Wyn Griffiths, Lucy Musson, Christopher McDermott","doi":"10.1080/17582024.2025.2506954","DOIUrl":"https://doi.org/10.1080/17582024.2025.2506954","url":null,"abstract":"Objectives: To explore healthcare professionals' experiences managing cough and secretion problems in Amyotrophic Lateral Sclerosis (ALS).Methods: A qualitative study was completed with 23 individuals participating in four focus groups. Data was analyzed using reflexive thematic analysis and COM-B and theoretical domains framework (TDF) behavior change frameworks.Results: This study found that roles, responsibilities, and expectations needed to be clearly defined and that building relationships was important to support care delivery. Barriers identified included limited access to specialist care, equipment, and opportunities to gain knowledge and skills. A structured clinical assessment was highlighted to enable good-quality care. Data mapped most commonly to the environmental context/resources, knowledge, skills (TDF), and physical capability (COM-B) behavior change domains.Conclusion: Cough and secretion management in ALS is complex due to the multifaceted nature of the disease. This study emphasizes the need for future development of clinical interventions to support care.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-12"},"PeriodicalIF":2.3,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges in managing comorbidities among people with dementia in low- and middle-income countries. 在低收入和中等收入国家管理痴呆症患者合并症方面的挑战。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-05-16 DOI: 10.1080/17582024.2025.2506337

Manuella Zandoná, Raphael Machado Castilhos

引用次数: 0

Characteristics of responders to interventions for Parkinson disease: a scoping systematic review. 帕金森病干预反应者的特征：范围系统评价。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-30 DOI: 10.1080/17582024.2025.2493465

Sidney T Baudendistel, Gammon M Earhart

{"title":"Characteristics of responders to interventions for Parkinson disease: a scoping systematic review.","authors":"Sidney T Baudendistel, Gammon M Earhart","doi":"10.1080/17582024.2025.2493465","DOIUrl":"https://doi.org/10.1080/17582024.2025.2493465","url":null,"abstract":"Aims: The purpose of this review is to identify the characteristics of responders in interventions targeting motor function for individuals with Parkinson disease.Materials & methods: The primary search included, 'Parkinson' + 'responder.' A second, broader, search further included 'response' + 'responsiveness' + 'responsive.' Records were sorted by intervention: neuromodulation, pharmaceutical, physical, and placebo.Results: Thirteen studies were identified in the primary and 19 studies in the secondary search, culminating in 120 characteristics. For neuromodulation interventions, responders were younger at onset, more responsive to levodopa, and had more difficulties with activities of daily living. Responders to pharmaceuticals were younger at diagnosis. Physical intervention responders had worse balance, less balance confidence, and worse cognition. No relevant characteristics were identified for placebo interventions.Conclusions: Although there are clear limitations and gaps in the literature, responder analyses represent an important step toward more personalized treatments for the motor symptoms of Parkinson disease.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-14"},"PeriodicalIF":2.3,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced Parkinson's disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study. 摩洛哥晚期帕金森病和器械辅助治疗的资格：一项多中心横断面研究

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-03-24 DOI: 10.1080/17582024.2025.2481818

Mohamed Daghi, Zineb Serhier, Abdelhakim Lakhdar, Hicham El Otmani

{"title":"Advanced Parkinson's disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study.","authors":"Mohamed Daghi, Zineb Serhier, Abdelhakim Lakhdar, Hicham El Otmani","doi":"10.1080/17582024.2025.2481818","DOIUrl":"10.1080/17582024.2025.2481818","url":null,"abstract":"Aim: This study investigates the prevalence and clinical features of advanced Parkinson's disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG).Methods: We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility.Results: This study included 370 patients with Parkinson's disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, p = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, p < 0.001). Additionally, premotor REM sleep behavior disorder increased the odds of LCIG eligibility (ORa = 2.38, p = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, p = 0.038).Conclusion: Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"65-76"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does menopause affect MS progression? Evidence and ongoing debates. 更年期会影响MS的进展吗？证据和正在进行的辩论。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-04-07 DOI: 10.1080/17582024.2025.2489878

L Lorefice, E Ferraro

引用次数: 0